… have been made to extend the potential usage of HIF-PHIs beyond anemia. This paper
reviewed the progress of preclinical and clinical research on clinically available HIF-PHIs in …

… In this review, we present the basic and clinical potential of PHD-i treatment in different
scenarios, such as ischemic heart disease, cardiac hypertrophy and heart failure, and their …

… In this review, we systemically review target validation, hit identification, and further key
clinical trials of roxadustat. The prospective clinical applications of PHD inhibitors are then …

… inhibitors enabled by combining SBDD approaches with high-throughput screening. Finally,
we highlight the clinical implications of small molecule PHD inhibitors… a hydroxylase inhibitor …

… inhibitors may not have the risk for cardiovascular side effects that occur due to high levels
of plasma EPO. Prolyl hydroxylase inhibitors … PHD inhibitors are in various phases of clinical …

… response is orchestrated by HIF prolyl hydroxylase domain-containing enzymes (PHDs), …
pharmacological inhibition of PHDs (prolyl hydroxylase domain-containing enzyme inhibitors […

… of HIF hydroxylases and possible modes of inhibition To place studies on the therapeutic
modulation of the HIF hydroxylases (including the potential for specific inhibition) in context, we …

… a consequence were concerned only with 17ahydroxylation inhibitors." Structures 4—> 10
… ) as potent inhibitors of adrenal 17a-hydroxylase [67] and also of testicular 17ahydroxylase […

… Time dependent HIF stabilization with prolyl hydroxylase inhibitors. We then investigated
potential time dependent effects of the inhibitors on HIF-α stabilization in Hep3b cells (Fig. 5A). …

… Significance: In this review, we have discussed the efficacy and effect of small molecules
that act as prolyl hydroxylase domain inhibitors (PHDIs). The use of these compounds causes …